C12N 2760/12111
Hantavirus
Official title: Hantavirus, e.g. Hantaan virus
C12N2760/12111 (Hantavirus) appears on 31 US grants and 32 published applications in this corpus.
Search patents in C12N- Granted patents
- 31
- Published applications
- 32
- Assignees
- 29
- Inventors
- 69
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 4 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 3 |
| 2012 | 1 | 0 |
| 2013 | 0 | 2 |
| 2014 | 1 | 2 |
| 2015 | 1 | 0 |
| 2016 | 1 | 3 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 2 |
| 2021 | 3 | 2 |
| 2022 | 0 | 3 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/12122New viral proteins or individual genes, new structural or functional aspects ofIndexing code23
- C12N 2760/12134Use of virus or viral component as vaccineIndexing code16
- C12N 2760/12171Demonstrated in vivo effectIndexing code7
- C12N 2760/12121Viruses as suchIndexing code6
- C12N 2760/12151Methods of production or purification of viral materialIndexing code5
- C12N 2760/12141Use of virus, viral particle or viral elements as a vectorIndexing code3
- C12N 2760/12123Virus like particles [vlp]Indexing code0
- C12N 2760/12131Uses of virus other than therapeutic or vaccineIndexing code0
All 12 subgroupsShow fewer
Recent patents
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines27 Jan 2026US 12,533,410 B2Arcturus Therapeutics, Inc.
- Systems and methods for the production of human polyclonal antibodies16 Dec 2025US 12,497,443 B2Sab, LLC
- Stabilized recombinant hantaviral spike proteins comprising mutations in Gc15 Aug 2023US 11,723,968 B2FundacióN Ciencia Para La Vida
- Sin Nombre virus full-length M segment-based DNA vaccines26 Oct 2021US 11,155,834 B2The Government of the United States, as represented by the Secretary of the Army
- Systems and methods for the production of human polyclonal antibodies27 Jul 2021US 11,072,649 B2Sab, LLC
- Systems and methods for the production of human polyclonal antibodies11 Jun 2026US 2026/0159574 A1Sab, LLC
- mRNA Vaccines Against Hantavirus24 Apr 2025US 2025/0127870 A1Board of Regents, The University of Texas System
- Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses9 May 2024US 2024/0150409 A1ISD Immunotech ApS
- Immunogenic formulation containing a modified bcg strain expressing an andesvirus protein (andv) useful for preventing and treating hanta-andv virus infections7 Dec 2023US 2023/0390378 A1Pontificia Universidad Catolica De Chile
- Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines7 Dec 2023US 2023/0390389 A1Arcturus Therapeutics, Inc.
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Antigen library immunization76US 6,541,011 B2Maxygen, Inc. · 2003
- Modified recombinant vaccinia virus and expression vectors thereof65US 5,762,938 AVirogenetics Corporation · 1998
- Alvac canarypox virus recombinants comprising heterlogous inserts56US 5,756,103 AVirogenetics Corporation · 1998
- Trova fowl pox virus recombinants comprising heterologous inserts16US 5,766,599 AVirogenetics Corporation · 1998